Figure 1


A
IFN-γ producing spots/one million cells
500
400
300
200
100
0
B pVAC1 + vehicle
C pVAC1 + imiquimod
B pVAC1.PR + vehicle
C pVAC1.PR + imiquimod

5

Figure 2


ccpm - backrground ccpm
150000
100000
50000
0
pVAC1 + vehicle
pVAC1 + imiquimod
pVAC1.OVA + vehicle
pVAC1.OVA + imiquimod

Figure 3


IL-2 producing spots/one million cells
600
500
400
300
200
100
0
pVAC1 + vehicle
pVAC1 + imiquimod
pVAC1.OVA + vehicle
pVAC1.OVA + imiquimod

Figure 4


IFN-γ
spots/million cells
120
100
80
60
40
20
0
IL-4
spots/million cells
350
300
250
200
150
100
50
0
pVAC1 + vehicle
pVAC1 + imiquimod
pVAC1.OVA + vehicle
pVAC1.OVA + imiquimod

Figure 5


spots/million splenocytes
1000
800
600
400
200
0
in vitro restimulation with Gag peptide
in vitro restimulation with Nef peptide
WRG7077 + vehicle
WRG7077 + imiquimod
WRG7077. Gag/Nef + vehicle
WRG7077. Gag/Nef + imiquimod
534.00.23post boost

Figure 6A



Figure 6B



Figure 7A



Figure 7B



Figure 8


IFN-γ ELISPOT with Gag peptide
day 6 post boost
WRG7077
WRG7077Gag/Nef
day11 post boost
WRG7077
WRG7077Gag/Nef
IFN-γ ELISPOT with Nef peptide
day 6 post boost
WRG7077
WRG7077Gag/Nef
day 11 post boost
WRG7077
WRG7077Gag/Nef
vehicle
imiquimod s.c.
Aldara
534.01.13plot5

Figure 9


—□—pVAC1 + vehicle
—○—pVAC1 + imiquimod
—△—pVAC1.OVA + vehicle
—▽—pVAC1.OVA + imiquimod
tumour volume (mm3)
0
200
400
600
800
1000
10
20
30
40
50
60
days post tumour implant
534010Bgraph2

Figure 10

Group	*% tumourigenicity (56 days post-implantation)*
pVAC1 + vehicle	41
pVAC! + imiquimod	58
pVAC1.OVA + vehicle	41
pVAC!.OVA + imiquimod	25

5